ESMO WORLD CONGRESS ON GASTROINTESTINAL CANCER

ESMO 18th World Congress on Gastrointestinal Cancer 2016

 

June 29 - July 2, 2016 Barcelona
Close
N. Poster
Poster title
Applicant name
Status
  2-PD Response to chemotherapy and prognosis in metastatic colorectal cancer with deficient mismatch repair ALEXANDRA ALEX Received Received
  2-P Suppression of Lipocalin-2 promotes the Epithelial-to-Mesenchymal Transition in human colorectal cancer cells Se Lim Kim Received Received
  2-RM Molecular characterization of gastrointestinal stromal tumours GISTs : The experience ofHassan IIUniversity Hospital-Fez; Morocco doumbia hamidou dioba Received Received
  3-P EXTENDED MUTATIONAL PROFILING FOR METASTATIC COLORECTAL CANCER (CRC): BEYOND RAS MOLECULAR SPECTRUM OF KRAS-NRAS-BRAF AND PI3K IN CANCER COLORECTAL. SILVINA OTERO Received Received
  3-PD Analysis of single-nucleotide polymorphisms (SNPs) in thephase 3 CORRECT trial of regorafenib vs placebo in patientswith metastatic colorectal cancer (mCRC) Dieter Lambrechts Received Received
  3-O Long term follow up in the SCALOP-1 trial: a randomised Phase II trial of induction chemotherapy followed by gemcitabine or capecitabine based chemoradiotherapy for locally advanced non-metastatic pancreatic cancer Somnath Mukherjee Received Received
  4-O Effects of nal-IRI (MM-398) 5-Fluorouracil on Quality of Life (QoL) in NAPOLI-1:A Phase 3 Study in Patients With Metastatic Pancreatic DuctalAdenocarcinoma (mPDAC) Previously Treated With Gemcitabine-Based Therapy Richard Hubner Received Received
  4-PD Lactate dehydrogenase (LDH) levels predict benefit from the continuation of bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): subgroup analysis of the randomized BEBYP study Federica Marmorino Received Received
  5-PD Clinical validation of response and resistance factor candidates to targeted therapy in gastric cancer Florian Lordick Received Received
  5-O Comparative molecular analyses of esophageal adenocarcinoma, esophageal squamous cell carcinoma, and gastric adenocarcinoma - and impact on outcome Joanne Xiu Received Received
  6-PD Final Analysis of Stage 1 Data From a Randomized Phase 2 Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine in Stage IV Previously Untreated Pancreatic Cancer Patients, Utilizing Ventana Companion Diagnostic Assay Joseph Takacs Received Received
  6-P Hypermethylation of APC, CDH13, MLH1, MGMT, P16 and RASSF1A promoter regions in patients with colorectal cancer Denis Kutilin Received Received
  7-O Biomarker Analyses of Second-Line Ramucirumab in Patients With AdvancedGastric Cancer From RAINBOW, a Global, Randomized, Double-Blind, Phase 3 Study Eric Van Cutsem Received Received
  8-RM SURGICAL EMERGENCIES IN COLORECTAL MALIGNANCIES - PATIENT PROFILE ANALYSIS Bharathi Mohan Thangasamy Received Received
  9-O NETTER-1 Phase III: Efficacy and Safety Results in Patients with Midgut Neuroendocrine Tumors Treated with 177Lu-Dotatate ANNALISA ZANUSO Received Received
  9-PD Safety and efficacy of FOLFOXIRI with or without targeted agents as first-line treatment of ed elderly metastatic colorectal cancer patients: a pooled analysis of GONO studies. Mariaelena Casagrande Received Received
  11-RM Safety and Efficacy of Biweekly Cetuximab Based Chemotherapy for Patients with Metastatic Colorectal Cancer kamel ahmed Received Received
  11-P Tumor budding is associated with low expression of miRNA-148a and miRNA-625-3p in colorectal cancer Edita Baltruskeviciene Received Received
  11-O Modified FOLFOXIRI (mFOLFOXIRI) plus cetuximab (cet), followed by cet or bevacizumab (bev) maintenance, in RAS/BRAF wild-type metastatic colorectal cancer (mCRC): results of the phase II randomized MACBETH trial by GONO Carlotta Antoniotti Received Received
  12-P CCL2 expression is correlated with Snail expression and affects the prognosis of patients with gastric cancer Jia Zhang Received Received
  13-P Prognostic Significance of cyclin D1 and p21(WAF1/CIP1) in Gastric Cancer Vasiliki Michalaki Received Received
  13-O A NEW NOMOGRAM FOR ESTIMATING 12-WEEKS SURVIVAL IN PATIENTS (PTS) WITH CHEMOREFRACTORY METASTATIC COLORECTAL CANCER (mCRC) Filippo Pietrantonio Received Received
  13-PD Final survival results of a multicenter phase I/II study of TAS-102 with bevacizumab for metastatic colorectal cancer patients refractory to standard therapies (C-TASK FORCE) Takayuki Yoshino Received Received
  14-P Are RHOA, CSNK1A1, DVL2, FZD8 and LRP5 Genes Novel Biomarkers in theConversion from Intestinal Metaplasia to Gastric Cancer? Ufuk Demirci Received Received
  14-O Evaluation of depth of response within a volumetric model in patients withmetastatic colorectal cancer: results of the SIRFLOX study Farah Dunlop Received Received
  15-O Association Between Depth of Response and Survival Outcomes inRASWild-Type Patients With Metastatic Colorectal Cancer Receiving First-LineFOLFOX or FOLFIRI Plus Cetuximab Once Every 2 Weeks In The APEC Study Gino Randazzo Received Received
  15-RM Clinicopathological, epidemiological and outcome of treatment of advanced gastric cancer in Egypt: single institution experience Ahmed Gaballah Received Received
  15-P Detection of genes &1089;opy number variation as predictive markers for metastases in patients with gastric cancer Denis Kutilin Received Received
  16-P Circulating mRNA expression of CD133, SNAIL, ZEB1 and ZHX as biomarkers in gastric and esophageal cancer. Federico Longo Received Received
  16-PD Current results of a Phase I study of DKN-01 in combination with paclitaxel (P)in patients (pts) with advanced DKK1 esophageal cancer (EC) orgastro-esophageal junction tumors (GEJ) Cynthia Sirard Received Received
  16-RM Prognostic factors and assessment of postoperative chemoradiotherapy in gastric cancer Mghirbi Fahmi Received Received
  16-O A prognostic marker for colorectal cancer: combining analyses of ploidy and stroma Susan Fotheringham Received Received
  17-P ANALYSIS OF microRNA EXPRESSION IN GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS Sandra Jimena Vega Neira Received Received
  17-PD A population-based study of gastric adenocarcinoma in Central Norway 2001 - 2011 Erling A Bringeland Received Received
  17-RM Systemic chemotherapy in Advanced gastric carcinoma: A comparison of DCF versus CF; versus ECF regimens in clinical setting.A reterospective study PRAMILA KUMARI Received Received
  18-O Clinical application of targeted next generation sequencing for colorectal cancer patients: a multicentric Belgian experience Nicky DHaene Received Received
  18-RM PRECISE SELECTION OF METASTATIC GASTRIC CANCER PATIENTS FOR FIRST LINE, DOCETAXEL BASED CHEMOTHERAPY: A RETROSPECTIVE STUDY. PRAVEEN KUMAR KHATRI Received Received
  18-PD Risk Factors for Metachronous Gastric Carcinoma Development After Endoscopic Resection of Gastric Dysplasia ; Retrospective, Single Center Study Hee Seok Moon Received Received
  19-PD ARQ 087, an Oral Pan- Fibroblast Growth Factor Receptor (FGFR) Inhibitor, in Patients with Advanced and/or Metastatic Intrahepatic Cholangiocarcinoma (iCCA) Michele Droz Received Received
  19-P Use of serum levels of cytokine TGF &946;1 in detection of Hepatocellular carcinoma in patients with chronic liver disease Amila Mehmedovic Received Received
  21-O Tailored strategy for locally-advanced rectal carcinoma according to the tumor response to induction trichemotherapy: preliminary results of the French phase II multicenter GRECCAR4 trial. philippe rouanet Received Received
  21-PD A Single Centre Experience of the prognostic variables in Hepatocellular carcinoma (HCC) patients treated with Transarterial Chemoembolization Preetha Aravind Received Received
  22-P Predictive biomarkers of pathologic response to preoperative chemoradiotherapy in locally advanced rectal cancer Radmila Jankovic Received Received
  22-O A Multi-Institutional Phase 2 Study of Single Agent Nivolumab in Previously Treated Metastatic Squamous Cell Carcinoma of the Anal Canal (SCCA). Amir Mehdizadeh Received Received
  22-PD FOLFOXIRI as primary treatment for locally advanced unresectable pancreatic cancer (LAPC): a prospective study Caterina Vivaldi Received Received
  23-PD Safety Across Subgroups in NAPOLI-1: a Phase 3 Study of nal-IRI (MM-398) 5-Fluorouracil and Leucovorin Versus 5-Fluorouracil and Leucovorin in MetastaticPancreatic Cancer Previously Treated With Gemcitabine-Based Therapy Li-Tzong Chen Received Received
  24-PD Retrospective Analysis of Quality of life and early tumour Shrinkage During First-line FOlFOX4 Panitumumab in RAS Wild-type metastatic Colorectal Carcinoma Daniel Booth Received Received
  24-P Carcinoembryonic antigen (CEA) and the carcinoma antigen 19-9 (CA 19-9) together in early diagnosis of Stage I-II colorectal adenocarcinoma. A case-control study Franco Lumachi Received Received
  25-RM Chemoradiation for Unresectable Gall Bladder Cancer: Regional cancer centre study. PRAMILA KUMARI Received Received
  25-PD RECOURSE Trial: Impact of Adverse Events on Quality of Life and Duration of Trifluridine and Tipiracil (TAS-102) Treatment Josep Tabernero Received Received
  25-O First-Line FOLFOX-4 Cetuximab in Patients With RASWild-Type Metastatic Colorectal Cancer: The Open-Label,Randomized Phase 3 TAILOR Trial Gino Randazzo Received Received
  26-RM IN GASTROINTESTINAL CANCERS, PATIENTS PERSPECTIVES ON PALLIATIVE CHEMOTHERAPY : A PROSPECTIVE STUDY PRAVEEN KUMAR KHATRI Received Received
  26-O Combination of Encorafenib and Cetuximab With or Without Alpelisib in Patients With Advanced BRAF-Mutant (BRAFm)Colorectal Cancer: Phase 2 Results Josep Tabernero Received Received
  26-P Assessment of lymph nodes for micrometastasis in high risk patients with colorectal cancer Gulrukh Botiralieva Received Received
  26-PD Survival Outcomes in Patients with RAS Wild-type metastatic Colorectal Cancer Classified by Khne Prognostic Category and BRAF mutation Status: Retrospective Analysis of the PRIME Study Dan Booth Received Received
  27-P Cancer stem cells marker CD44 and NOTCH activation predict unfavorable prognosis in metastatic colon cancer patients treated with anti VEGF-therapy Francesca Negri Received Received
  28-PD Retrospective Analysis of Impact of Khne Prognostic Category and BRAF mutation Status on Survival in Patients with RAS Wild-type metastatic Colorectal Cancer treated With Second-line FOlFIRI With/Without Panitumumab Daniel Booth Received Received
  28-RM Gemcitabine in Combination With capcitabine Compared With Gemcitabine combined with Erlotinib in Locally Advanced or Metastatic Pancreatic Cancer PRAVEEN KUMAR KHATRI Received Received
  28-P Analysis of KRAS and NRAS mutations in Greek patients with metastatic Colorectal Cancer (mCRC) on the registry of the Gastro-intestinal Cancer Study Group (GIC-SG) john souglakos Received Received
  29-RM Outcome of continuous infusion of low dose gemcitabine in locally advanced and metastatic pancreatic carcinoma Salah Mabrouk Khallaf Received Received
  30-RM Phase III study of Capecitabine and Oxaliplatin versus 5-fluorouracil in Neoadjuvant Chemoradiation for Locally Advanced Rectal Carcinoma Marwa Khalaf Received Received
  30-P Tumor-infiltrating lymphocytes (TILs) density as prognostic determinant in stage II colorectal cancer Vincenzo Ricci Received Received
  31-PD An exploratory Study-level meta-Analysis Assessing the Impact of early tumour Shrinkage on Overall Survival in Patients with RAS Wild-type metastatic Colorectal Cancer Receiving First-line treatment in three Randomised Panitumumab trials Daniel Booth Received Received
  31-RM Preoperative short-course chemoradiation with consolidation with consolidation chemotherapy and delayed surgery in locally advanced rectal cancer( T3-T4 or N ) Sarvazad Sotoudhe Received Received
  32-RM Neoadjuvant Chemoradiotherapy and Chemotherapy in Patients with Locally Advanced Rectal Cancer Marwa Khalaf Received Received
  32-PD Evolution of efficacy and safety of cetuximab with the determination of RAS status in Metastatic Colorectal Cancer (mCRC) elderly patients Fanny MARHUENDA Received Received
  32-P A complete blood count as a prognostic marker in patients with metastatic colorectal cancer (mCRC). Magdalena Krakowska Received Received
  33-RM Rectal Cancer in Patients Younger than 40 at AUBMC: Tumor Characteristics and Com- parative Survival and Disease Free Survival Ali Shamseddine Received Received
  34-PD Heterogeneity in the first-line treatment of patients with advanced or metastatic gastric cancer in the U.S. Thomas Abrams Received Received
  35-P Simultaneous carcinoembryonic antigen (CEA), carcinoma antigen 19-9 (CA 19-9) and 125 (CA-125) measurement in patients with STAGE IA-IB gastric cancer. A case-control study Franco Lumachi Received Received
  35-PD Efficacy and safety of second-line irinotecan based chemotherapy in early relapse patients with gastric cancer after adjuvant chemotherapy: Exploratory subgroup analysis of TRICS trial Kazuhiro Nishikawa Received Received
  36-P Long Interspersed Nuclear Element (LINE)-1 Methylation Level as a Molecular Marker of Early Gastric Cancer Soo A Choi Received Received
  36-PD Maintenance chemotherapy or Observation alone following Gemcitabine-Platinum combination palliative chemotherapy in locally advanced and/or metastatic gallbladder cancer - a single tertiary care centre experience in South Asia Rakesh pinninti Received Received
  37-RM Neo-adjuvant FOLFIRINOX in borderline resectable/locally advanced pancreatic adenocarcinoma Ali Shamseddine Received Received
  37-P The Role of Carcino-embryonic Antigen Testing among Western Patients with Resected Gastric Cancer Erin Greenleaf Received Received
  38-RM Modified GTX second-line therapy in pancreatic adenocarcinoma Ali Shamseddine Received Received
  39-PD Role of adjuvant radiotherapy following neo-adjuvant chemotherapy (NACT) and surgery in oesophageal cancer a multi-centre retrospective cohort study Somnath Mukherjee Received Received
  39-P 5-FU DEGRADATION RATE IN PATIENTS WITH RECURRENT GASTROINTESTINAL CANCER TREATED WITH METRONOMIC CAPECITABINE Michela Roberto Received Received
  40-PD Risk assessment for gastrointestinal cancers in patients with family history of gastrointestinal cancer: Multi-center interim analysis study in the Republic of Korea Joo Won Chung Received Received
  41-P IKAROS: a potential prognostic marker in pancreatic ductal adenocarcinoma. Marlid Cruz Received Received
  41-RM Risk of selected gastrointestinal toxicities in cancer patients treated with Pazopanib; a systematic review and meta-analysis lamiaa abdallah Received Received
  42-P The genetic profile of pancreatic circulating tumor cells Maria Papadimitriou Received Received
  43-P Significance of bcl-2 in rectal cancer recurrences Gulrukh Botiralieva Received Received
  43-RM Eruptive seborrheic keratosis (ESK) and its association with gastrointestinal cancer (GIC). A case-control study and meta-analysis Jesus Insuasty Received Received
  45-RM PRE-OPERATIVE DIAGNOSIS IN PANCREATIC TUMORS -REALITY OR MYTH? Dr. Bharathi Mohan Thangasamy Received Received
  45-P Resistant form of helicobacter pylori in development of stomach MALT lymphoma Makhsud Mallaev Received Received
  47-P Sorafenib after locoregional treatments for advanced or recurrent hepatocellular carcinoma Catarina Ribeiro Received Received
  48-P Prognostic Impact of CA19-9 Level at Diagnosis in Pancreatic Adenocarcinoma: A U.S. Population Study Katelin Mirkin Received Received
  49-P A population study of correlation between the treatment rate for monoclonal antibodies (Mabs) and mortality rate in patients with metastatic colorectal cancer (mCRC) in Russia Mikhail Fedyanin Received Received
  49-RM Colorectal cancer in Medan Indonesia. A single centre report Sry Widjaja Received Received
  50-RM Lifestyle habits and dietary patterns in gastric cancer patients in Toungoo; Myanmar Khin Khin Nwe Received Received
  50-P THE PHARMACOLOGICAL COSTS OF FIRST-LINE THERAPIES IN UNSELECTED ADVANCED COLORECTAL CANCER PATIENTS: A REVIEW OF PUBLISHED PHASE III TRIALS Jacopo Giuliani Received Received
  51-RM Evidence-based assessment of the burden of infection related solid tumors Ahmed Alnagar Received Received
  51-P Clinical and pathologic characteristics of patients treated in second-line (2L) with 25 cycles (Cy) or more of FOLFIRI Aflibercept (FA). Preliminary results. Carles Pericay Pijaume Received Received
  52-RM PANCREATIC CANCER OUR EXPERIENCE (EPIDEMIOLOGY). Recioui Abdallah Received Received
  53-RM A Clinico epidemiological study of non metastatic gastrointestinal stromal tumor A prospective observational multi institutional study from Southern India KRISHNAKUMAR RATHNAM Received Received
  55-P Prospective evaluation for chemotherapy-induced nausea and vomiting in colorectal cancer receiving oxaliplatin-based chemotherapy of moderate emetic risk Mototsugu Shimokawa Received Received
  56-P Outcome of Maintenance Therapy in Patients Who Achieved NED After Liver Resection for mCRC marwan al-hajeili Received Received
  57-P Body Composition, beyond Body Mass Index and sarcopenia, has a major prognostic impact on patients with refractory advanced Colorectal Cancer Camille Van Bogaert Received Received
  59-RM The effect of adjuvant chemotherapy folowing extended total gastrectomy for Siewerts type II adenocarcinoma of the esophagogastric junction Ramiz Bayramov Received Received
  61-P Use of aflibercept in colorectal cancer patients - real world experiences in the North West Nicola Flaum Received Received
  63-RM Neoadjuvant Chemotherapy for Unresectable Gall Bladder Carcinoma : Our experience Sandeep Bhoriwal Received Received
  63-P Effect of age on treatment effect and tolerability of SIRT when added to mFOLFOX chemotherapy inpatients with metastatic colorectal cancer (mCRC) results from the SIRFLOX study Farah Dunlop Received Received
  64-P Bevacizumab with chemodoublet as conversion-to-resectability therapy for patients with liver metastases of colorectal cancer Marija Ristic Received Received
  66-RM Histological diagnosis of gastric submucosal tumors after endoscopic submucosal dissection Olena Kuryk Received Received
  66-P New methods of detecting oxaliplatin-induced peripheral sensory neuropathy in colon cancer patients during adjuvant treatment with 5-fluorouracil/oxaliplatin Joanna Szpejewska Received Received
  68-P Cetuximab in addition to oxaliplatin, fluouracil and radiotherapy for patients with esophageal cancer treated without surgery Gabriella Alexandersson von Dbeln Received Received
  69-P Neoadjuvant chemotherapy for esophageal cancer: Comparison of DCS (DTX/CDDP/S-1) chemotherapy with FAN (5-FU/ADM/Nedaplatin) Hideaki Shimoji Received Received
  71-P Clinical relevance of histologic subtypes in esophageal carcinoma treatedwith neoadjuvant chemo-radiotherapy. Mariaiconcologia.net Saigí Received Received
  72-P Pattern of recurrence and efficacy of salvage therapy after relapse in locally advanced esophageal carcinoma treated with preoperative chemoradiotherapy plus surgery MARC OLIVA Received Received
  73-P Non surgical management of Oesophageal cancer- a retrospective audit with 10 year follow up Ravi Kodavatiganti Received Received
  74-P DISTANT OUTCOME OF PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE AND METASTATIC OESOPHAGEAL CANCER AFTER MULTIMODALITY TREATMENT Luiza Serbanescu Received Received
  76-P Integrating CROSS style chemotherapy regime into higher doses of radiation for the radical treatment of localized oesophageal carcinoma in patients with borderline fitness. Pei Shuen Lim Received Received
  81-P Phase II study of adjuvant chemotherapy with S-1 plus Oxaliplatin for gastric cancer Lin Yang Received Received
  82-P Three years of metastatic gastric cancer follow up in our hospital Marta Ferrer Received Received
  86-P Clinical outcome after Endoscopic Submucosal Dissection for Early Gastric Cancer of Absolute and Expanded Indication ; Retrospective Single Center Study HYUK SOO EUN Received Received
  87-P A phase II study of a combination treatment of alternate-day S-1 and lentinan as first-line chemotherapy for unresectable or recurrent gastric cancer Shigefumi Yoshino Received Received
  92-P PERIOPERATIVE CHEMOTHERAPY IN GASTRIC ADENOCARCINOMA- PROGNOSTIC FACTORS IDENTIFICATION Cristiana Marques Received Received
  93-P IS THERE STILL A ROLE FOR ADJUVANT RADIOTHERAPY IN THE CASE OF PATIENTS WITH PRIMARY RESECTABLE GASTRIC CANCER? Luiza Serbanescu Received Received
  94-P Early and long-term outcomes of gastric cancer patients treated with perioperative chemotherapy and radical surgery in a single cancer center Paulyne Viapiana Received Received
  97-P Hepatic Artery Embolization (HAE) In Hepatocellular and Gastroenteropancreatic Neuroendocrine Tumors at Instituto Oncologico Nacional. Panama. Omar Castillo-Fernandez Received Received
  98-P Prognostic Significance of Comorbidities in elderly patients with Hepatocellular carcinoma (HCC) treated with Transarterial Chemoembolization: A Single Centre Experience Preetha Aravind Received Received
  102-P Effectiveness of TACE as bridge therapy for liver transplant in hepatocellular carcinoma Catarina Ribeiro Received Received
  103-P Prognostic factors for survival in patients with advances intrahepatic cholangiocarcinoma treated with gemcitabine plus cisplatin as first line treatment Utako Ishimoto Received Received
  104-P A pilot study of concurrent chemoradiotherapy with gemcitabine and cisplatin in patients with locally advanced biliary tract cancer Hee Man Kim Received Received
  105-P Surveillance CT in patients with complete remission following curative chemoradiotherapy for Anal Cancer (Single Centre experience) Christos Mikropoulos Received Received
  106-P M.D., Ph.D. Seung Taik Kim Received Received
  107-P EPIDEMIOLOGY OF LYMPHOMAS INVOLVING THE GASTRO INTESTINAL TRACT : A MULTICENTRE RETROSPECTIVE STUDY FROM SOUTHERN INDIA KRISHNAKUMAR RATHNAM Received Received
  108-P Role of adjuvant treatment in periampullary carcinoma Saphalta Baghmar Received Received
  109-P MALT-Lymphoma - always a good prognosis? Garcia Ana Rita Received Received
  111-P Correlation of Mitotic Index and Ki-67 and Their Impacts on Survival of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) at Ramathibodi Hospital THITIYA DEJTHEVAPORN Received Received
  112-P Weekly gemcitabine for the treatment of biliary tract and gallbladder cancer. PRAMILA KUMARI Received Received
  115-P Weight Loss during 1st-line chemotherapy for upper gastrointestinal malignancies (UGI) may impact survival and access to further treatment lines Georgios Oikonomopoulos Received Received
  116-P PALLIATVE THERAPY IN UNRESECTABLE ADVANCED GALL BLADDER CANCERS, A RETROSPECTIVE STUDY PRAVEEN KUMAR KHATRI Received Received
  117-P Phase II study of combination chemotherapy of gemcitabine/S-1 with nafamostat mesilate for advanced unresectable pancreatic cancer: First report. Tadashi Uwagawa Received Received
  119-P Chemoradiotherapy versus chemotherapy alone for unresectable locally advanced pancreatic cancer: a retrospective cohort study Yuta Maruki Received Received
  120-P Gemcitabine nab-paclitaxel as first-line chemotherapy for Japanese patients with advanced pancreatic cancer in real-world clinical practice: a retrospective study Toshifumi Yamaguchi Received Received
  121-P Phase Ib trial of oxaliplatin, UGT1A1 genotype-directed dosing of irinotecan and chronomodulated capecitabine (OXIRI) chemotherapy in patients with advanced pancreatic cancer Matthew Chau Received Received
  122-P Phase I study of S-1, irinotecan plus oxaliplatin combination therapy (S-IROX) for unresectable pancreatic ductal adenocarcinoma Mitsuhito Sasaki Received Received
  123-P Clinical Experience of the Efficacy and Safety of two FOLFIRINOX Variants for Inoperable Pancreatic Cancer Malcolm Buhagiar Received Received
  124-P FOLFIRINOX in borderline resectable pancreatic carcinoma Esther Una Cidon Received Received
  125-P Gemcitabine-induced pseudocellulitis in patients with pancreatic adenocarcinoma or cholangiocarcinoma Esther Una Cidon Received Received
  126-P PANOVA: A pilot study of TTFields concomitant with gemcitabine for front-line therapy of advanced pancreatic adenocarcinoma Ori Farber Received Received
  128-P Outcomes with Watch-and-Wait after Pelvic Radiotherapy for Rectal Cancer in East Kent Rakesh Raman Received Received
  129-P Survival rates of patients with rectal cancer in the Department for General and Abdominal surgery University Clinical Center Maribor, who underwent surgery between 2004 and 2014 Nuhi Arslani Received Received
  130-P Impact of age on efficacy of neoadjuvant chemoradiotherapy (CRT) in locally advanced rectal cancer (LARC) German Calderillo Received Received
  132-P The impact of obesity on complete pathologic response to neoadjuvant chemoradiotherapy in rectal cancer patients Consuelo Diaz Received Received
  133-P ASSESSMENT OF SEXUAL DYSFUNCTION IN RECTAL CANCER SURVIVORS Joana Rodrigues Received Received
  134-P Parthenolide suppresses hypoxia-induced angiogenesis and epithelial-mesenchymal transition by regulating hypoxia inducible factor 1 alpha signaling in colorectal cancer Se Lim Kim Received Received
  135-P The role of Angiotensin II subtype IA receptor on liver metastasis formation YUKI SHIMIZU Received Received
  137-P Macrophage coculture enhanced invasion of gastric cancer cells via FOXQ1 pathway Jia Zhang Received Received
  138-P Is HER2 positivity gastric cancer good prognostic sign?- our experiences Milka Vjetica Received Received
  139-P Monitoring of plasma concentrations of erlotinib (ERL) after long time administration of 100mg in advanced pancreatic cancer patients Azra Sahmanovic Received Received
  140-P Significant intraoperative blood loss predicts poorprognosis after hepatectomy following neoadjuvantchemotherapy for liver-only colorectal metastases Mafalda Costa Neves Received Received
  141-P Treatment approaches for resectable colorectal cancer metastases in the liver exhibiting poor prognosis Sergey Khays Received Received
  142-P Experience with Aflibercept as a second line chemotherapy in metastatic colorectal cancer. Encarnación González-Flores Received Received
  143-P The evaluation of liver resection for colorectal cancer liver metastasis Masaichi Ogawa Received Received
  144-P ANTI-EGFR MONOCLONAL ANTIBODIES AND SURGERY OF METASTASES IN THE TREATMENT OF METASTATIC COLORECTAL CANCER (mCRC) Anna Storozhakova Received Received
  145-P Metastases resection following FOLFIRI-aflibercept in refractory patients to first-line chemotherapy: safety and efficacy analysis Andres Muñoz Martín Received Received
  146-P Colorectal cancer patients with lung-only metastases have a favorable prognosis irrespective of treatment Moran Gadot Received Received
  147-P Final analysis : Phase II trial of Irinotecan/S-1/Cetuximab (IRIS/Cet) as second line treatment in patients with KRAS exon2 wild type mCRC : HGCSG0902. -Comparison of administration interval in Cetuximab treatment. Satoshi Yuki Received Received
  148-P RECURRENCE FREE SURVIVAL AS A PUTATIVE SURROGATE FOR OVERALL SURVIVAL IN PHASE III TRIALS OF CURATIVE-INTENT TREATMENT OF COLORECTAL LIVER METASTASES: SYSTEMATIC REVIEW Raphael Araujo Received Received
  149-P Impact of Sequence of Biologic therapies on Overall Survival in Patients with RAS Wild-type metastatic Colorectal Carcinoma: An exploratory, Retrospective Pooled Analysis Daniel Booth Received Received
  150-P Locoregional therapy in liver dominant metastatic colorectal cancer having failed standard drug therapy: Outcome and prognostic parameters in 133 consecutive patients Stefan Pluntke Received Received
  151-P The expression of proliferating cell nuclear antigen (PCNA) and Ki-67 in patients with colorectal adenocarcinoma and lymph node metastases Franco Lumachi Received Received
  152-P Observational Cohort Study of 1st line Bevacizumab Combined with Chemotherapy in Metastatic Colorectal Cancer (HGCSG0802): Sub-group Analysis by the Glasgow Prognostic Score (GPS). Takuto Miyagishima Received Received
  154-P Combined oxaliplatin, irinotecan and fluorouracil as a rescue regimen for heavily pretreated metastatic colorectal cancer (mCRC) patients Marcela Crosara Teixeira Received Received
  155-P Unresectable colorectal cancer liver metastases: retrospective review and survival analysis lourdes calera Urquizu Received Received
  156-P Pathologic response of liver metastases from colorectal cancer after chemotherapy and aflibercept. Initial report of 23 cases from 9 patients Frédéric Bibeau Received Received
  157-P A phase II study of XELOX and Cetuximab (Erbitux) as first-line therapy in patients with KRAS wild-type metastatic colorectal cancer (FLEET2) Shigeyoshi Iwamoto Received Received
  158-P RADIOEMBOLIZATION (SIRT) AS A CONSOLIDATION TREATMENT IN COLORECTAL LIVER METASTASES AFTER FIRST LINE CHEMOTHERAPY: EFFICACY AND SAFETY. SALVATORE CAPONNETTO Received Received
  159-P Regorafenib vs TAS-102 as salvage-line treatment in patients with metastatic colorectal cancer refractory to standard chemotherapies: a multicenter retrospective comparison study hironaga satake Received Received
  160-P Impact of KRAS mutation on patterns of metastasis in a series of colorectal cancer patients Marta Domenech Viñolas Received Received
  161-P 5-FU based chemotherapy with Bevacizumab in synchronous metastatic colorectal cancer patients with bleeding primary tumor Birgit Gruenberger Received Received
  162-P IS RESECTION THE ONLY CHOICE FOR THE TREATMENT OFBILOBAR COLORECTAL CANCER METASTASES? Antonio Chiappa Received Received
  164-P Synchronous disease does not predict long-term outcomes in patients with resected colorectal cancer liver metastases Marcio Marques Received Received
  165-P Efficacy and toxicity of FOLFIRI / aflibercept in second line colorectal cancer in real life population, retrospective study. Does first line matters? Nieves Martinez Lago Received Received
  166-P Re-hepatectomy is a predictor of long-term survival in patients that recur after liver resection of colorectal liver metastases Marcio Marques Received Received
  167-P Cetuximab rechallenge in metastatic colorectal cancer patients Amanda Nogueira Received Received
  168-P Retrospective comparison of efficacy and safety of docetaxel and weekly-paclitaxel as 2nd-line chemotherapy for patients with unresectable or recurrent esophageal cancer Hiroshi Nakatsumi Received Received
  169-P Outcomes of metastatic gastroesophageal cancer patients treated with third line therapy: A 5-year retrospective analysis at a single centre Chau Ng Received Received
  170-P A Biweekly S-1 and nab-paclitaxel as first-line chemotherapy in patients with unresectable or recurrent gastric cancer Lin Yang Received Received
  171-P The impact on survival of CPT-11 as third-line or later treatment in advanced gastric cancer. Akitaka Makiyama Received Received
  172-P Intraperitoneal aerosol chemotherapy (PIPAC) is a new approach in the treatment of patients with peritoneal сarcinomatosis Anna Utkina Received Received
  173-P OUTCOMES OF PALLIATIVE GASTRECTOMY IN 549 ASYMPTOMATIC PATIENTS WITH ADVANCED GASTRIC CANCER Valentina Fanotto Received Received
  174-P Ramucirumab and Paclitaxel in Platinum-refractory Advanced or Metastastic Gastric or Gastroesophageal Junction Adenocarcinoma a Single Center Experience Ursula Vogl Received Received
  175-P EFFECTIVENESS OF SORAFENIB IN THE TREATMENT OF HEPATOCELLULAR CARCINOMA Paulo Salamanca Received Received
  177-P Stereotactic Radiotherapy (SRT) versus Whole Brain Radiotherapy (WBRT) in the management of 1-3 brain metastases (BM) originating from a gastrointestinal (GI) tract malignancy. Pei Shuen Lim Received Received
  178-P Capecitabine and temozolomide (CAPTEM) in patients with advancedneuroendocrine tumors: the experience of a portuguese cancer center. Andreia Chaves Received Received
  182-P An experience of FOLFIRINOX chemotherapy in advanced Pancreatic Cancer Yazan Haddadin Received Received
  183-P Abrogation of alcohol dehydrogenase-1B (ADH1B) expression by CD90 stromal cells supports tumor-promoting inflammation in colorectal cancer Romain Villéger Received Received
  185-P Overexpression of SIRT 6 induces apoptosis in hepatocellular carcinoma mediated by Wnt/&946;-catenin signaling pathway SOO MI KIM Received Received
  189-P Evaluation of short-term quality of life changes after surgery in elderly patients with colorectal cancer using the Medical Outcomes Study short form (MOS-SF-36) questionnaire Franco Lumachi Received Received
  192-P Ocular toxicities with oxaliplatin continue overlooked Esther Una Cidon Received Received
  195-P The impact on comorbidities in deciding the dose for the first cycle of chemotherapy Esther Una Cidon Received Received
  196-P Gastrointestinal stromal tumors: Fifteen years of experience in a Portuguese Hospital Centre Sílvia Lopes Received Received
  197-P INTRAOPERATIVE SENTINEL LYMPH NODE POSITIVITY BY METHYLENE BLUE DYE AND ITS ASSOCIATION WITH OTHER DISSECTED LYMPH NODE BY HISTOPATHOLOGICAL EXAMINATION IN COLORECTAL CANCER Dr.Bharathi Mohan Thangasamy Received Received
  199-P Dosing first cycle of chemotherapy in colorectal cancer: is BSA used for everybody? Esther Una Cidon Received Received
  200-P A Study on Response for Irreversible Electroporation of Colon Cancer Cell using Multiphoton Microscopy Jung Min Lee Received Received
  201-P A Comparative Study for Effectiveness of Irreversible Electroporation Ablation according to Therapeutic Method: Colon Cancer Animal Model Jung Min Lee Received Received
  203-P Assessing intratumor heterogeneity and evolutionary distance in exome sequencing of colon cancer Ulrich Popper Received Received
  206-P Effects of eribulin mesilate for tumor progression and fibrosis in gastric cancer Toru Kurata Received Received
  207-P Protective Effect of Ursodeoxycholic acid in the Chemotherapy Induced Mucositis : an In Vitro Animal Experiment Jung Min Lee Received Received
  208-P Pre-therapy functional and body status of patients with advanced gastrointestinal cancer compared to breast cancer patients and healthy women Katrin Stuecher Received Received
  209-P Maintenance BEZ235 treatment following BEZ235 and radiation treatment prolongs the therapeutic effect in colorectal cancer Ming-Feng Wei Received Received
  212-P An investigation of the association between sarcopenia and post-operative morbidity and mortality in patients with gastric cancer Stephen OBrien Received Received
  214-P Salvage Chemoradiotherapy for Locally Recurrent Bile Duct Cancer Jeong Il Yu Received Received
  216-P Treatment of squamous cell anal cancer with IMRT and simultaneous hypofractionated boost combined with concurrent chemotherapy Laura Diaz Received Received
  217-P Chemoradiotherapy with IG - VMAT & IG - IMRT to treat Squamous Anal Cancer Peter Correa Received Received
  222-P Comparison of Investigator-Delineated Gross Tumor Volumes and Quality Assurance in Pancreatic Cancer: Analysis of the On-trial cases for the SCALOP Trial SOMNATH MUKHERJEE Received Received
  224-P Locally advanced rectal cancer:A single institution experience Nuria Dueñas Received Received
  226-P Rectal Bioelectrical impedance (REBI) as a possible screening tool for colorectal cancer (CRC) Edelberto Mulett Received Received
  227-P Comparative characteristics of somatic mutations in the KRAS gene in patients with colorectal cancer the South of Russia Denis Kutilin Received Received
  228-P Inhibitory effects of Lactobacillus helveticus SBT2171 on the proliferation of colorectal tumor cells and the action mechanism Kazunobu Baba Received Received
  229-P An Evaluation Based on a Systematic Review of Epidemiologic Evidence of Colorectal Cancer Risk among the Alcohol Consuming Indian Population DR ANCHAL NAVNEET MISHRA Received Received
  230-P Muir-Torre Syndrome diagnostic and screening. A single center experience Elizabeth Inga Received Received
  231-P PHYSICAL ACTIVITY AND BARRETTS OESOPHAGUS Sylwia Gugala Received Received
  232-P The value of echinococcosis in development of liver cancer. Aziza Almanova Received Received
  234-P Incidence of Sarcopenia and its relationship with Body Mass Index in colorectal cancer patients. Vasileios Alivizatos Received Received
  235-P HOW OFTEN DOES THE PATIENT REPEAT SCREENING COLONOSCOPY?; A STUDY FOR PERSONALIZED RECOMMENDATION OF SCREENING COLONOSCOPY INTERVAL Jung Min Lee Received Received
  236-P Screening Practices of Australians Following Partial Roll-out of the National Bowel Cancer Screening Program, 2009-2012 Louisa Flander Received Received
  237-P Comparison of adenoma detection by polypectomy during both insertion and withdrawal versus only withdrawal of colonoscopy: a randomized, controlled multicenter trial Jeong-Seon Ji Received Received
  240-P Vitamin D levels in oesophageal and gastric cancer patients and their outcome Subodha Thanthulage Received Received
  242-P MORTALITY TREND FOR HEPATOCELLULAR CARCINOMA IN ALBANIA: A HEPATITIS B VIRUS ENDEMIC AREA Fatjona Kraja Received Received
  243-P Undiagnosed chronic liver disease (CLD) in patients presenting with Hepatocellular Carcinoma (HCC) Pavlina Spiliopoulou Received Received
  244-P Cholangiocarcinoma: A restrospective analysis of our experience in diagnosis, prognostic factors, staging and treatment. Elizabeth Inga Received Received
  246-P Survival Patterns of Stage IV Pancreatic Cancer: a Population-Based Study Mohammed Mousa Received Received
  247-P Young patients under 40 age with colorectal cancer have poor survival PRAMILA KUMARI Received Received
  248-P Helicobacter pylori translocation to the regional lymph nodes in patients with gastric carcinoma Paulyne Viapiana Received Received
  249-P Short-term results of surgery in elderly (65 years) versus younger patients with Stage I-II colonic adenocarcinoma. A case-control study Franco Lumachi Received Received
  253-P Multimodal analgesia combined with epidural anesthesia and intravenous administration of acetaminophen in perioperative management of esophagectomy using modified ERAS protocol Takashi Ogata Received Received
  254-P Esophagectomy with cervical anastomosis has a greater need for intervention for dysphagia than intrathoracic anastomosis Yaron Perry Received Received
  257-P Surgical treatment of patients withneuroendocrine neoplasms of the stomach Ivan Peregorodiev Received Received
  258-P 5-Year Survival of Gastric Cancer Patients after Radical Surgery was Significantly Depended on Tumor Characteristics, Blood Cell Circuit, Cell Ratio Factors, Hemostasis System and Adjuvant Treatment Oleg Kshivets Received Received
  259-P Laparoscopic gastrectomy: our technique, complications and long-term oncological results. Dmytro Golub Received Received
  260-P Outcomes of laparoscopic and open gastrectomy for gastric cancer: a comparative analysis Bárbara Castro Received Received
  261-P SURVIVAL AND DISEASE-FREE SURVIVAL IN A CONSECUTIVE MONOCENTRIC SERIES OF MORE THAN 1000 D-2 GASTRIC RESECTION FOR CANCER Antonio Chiappa Received Received
  262-P Multivisceral resections for gastric cancer - Should all patients with locally-disease receive them? Paulyne Viapiana Received Received
  263-P Laparoscopic versus open distal gastrectomy for gastric cancer: a single-center case-control study Bárbara Castro Received Received
  264-P Is laparoscopic approach an option in resection of advanced gastric cancer? Bárbara Castro Received Received
  266-P Highlight of benefits in cirrhotic patient of laparoscopic resection for malignant tumor, retrospective study with propensity score analysis Fabien Le Roux Received Received
  268-P SURGICAL OUTCOMES AND STRICT FOLLOW-UP OF RETROPERITONEAL SOFT-TISSUE SARCOMA Antonio Chiappa Received Received
  271-P Feasibility of neoadjuvant chemotherapy with modified FOLFOX6 (combination chemotherapy of infusional 5-FU/l-Leucovorin and intermittent oxaliplatin) with bevacizumab in patients with advanced lower rectal cancer. Chihiro Kosugi Received Received
  273-P Hepatectomy followed by adjuvant chemotherapy with capecitabine plus oxaliplatin for three months for liver metastases from colorectal cancer: a multicenter phase 2 study hironaga satake Received Received
  277-P A prospective, observational trial to assess the safety and efficacy of regorafenib in patients with metastatic colorectal cancer (mCRC) in routine clinical practice (CORRELATE) Michel Ducreux Received Received
  278-P Phase Ib/II study of nivolumab plus CAPIRI: Initial results of metastatic colon cancer and pancreatic adenocarcinoma patients. Vivek Khemka Received Received
  281-P JAVELIN Gastric 100: phase 3 trial of avelumab (anti-PD-L1 antibody) maintenance therapy vs continuation of first-line chemotherapy in patients with unresectable, locallyadvanced or metastatic gastric or gastro-oesophageal junction cancer Kathryn Boothroyd Received Received
  282-P JAVELIN Gastric 300: phase 3 trial of avelumab (anti-PD-L1 antibody) best supportive care (BSC) vs BSC chemotherapy as third-line treatment for advanced gastric or gastro-oesophageal junction cancer Kathryn Boothroyd Received Received
  285-P A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Ramucirumab Versus Placebo as Second-Line Treatment in Patients With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein Following First-Line Sorafenib (REACH-2) Emily Cullinan Received Received
  287-P Nanoliposomal Irinotecan (nal-IRI)-Containing Regimens Versus nab-PaclitaxelPlus Gemcitabine as First-Line Therapy in Patients With Metastatic PancreaticAdenocarcinoma: A Randomized, Open-Label Phase 2 Study Andrew Dean Received Received
  288-P Phase 3, Randomized, Double-Blind, Placebo-Controlled, Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) vs placebo, both with Nab-Paclitaxel and in pts With Previously Untreated, Hyaluronan (HA)-High, Stage IV Pancreatic Ductal Adenocarcinoma Joseph Takacs Received Received
  289-P Hepatic arterial infusion chemotherapy for unresectable liver metastases of colorectal cancer: a multicenter retrospective study Annie LIM Received Received
Tel.: +34 91 736 2385
LOCAL TIME
Contact: Katarina Gluic
Hours: 8:30-17:30 Fri 8:30-15:00
19:55
For help with a poster, please specify the poster number, the first author and the congress and we will reply shortly.
Poster no.
Contact name
E-mail
Telephone
Congress
Comments
Captcha image
 

ESMO WORLD CONGRESS ON GASTROINTESTINAL CANCER

ESMO 18th World Congress on Gastrointestinal Cancer 2016

 

June 29 - July 2, 2016 Barcelona
HELP LINE
Manage Orders
FAQs


Virtual Poster Gallery
Search and consult posters online
in an exclusive section
for each poster
    ACTIVE FROM 29/06/2016 TO 02/07/2017
Poster
Gallery
Oral Presentation
& Video Gallery
Poster Discussion
Forum
                   DOI: 10.3252/pso.eu.18wgic.2016 
PrintingOnline
Submit your poster online
in powerpoint format

   Poster submission deadline 30/06/2016
Upload Poster
Upload Oral Presentation of Video
Check your Poster
Upload
Poster
Upload Oral
Presentation or Video
Check
your Poster





PosterSessionOnline
Logo Draft
 
Logo Cert